Immunotherapy for Metastatic Kidney Cancer Shows Increased Survival
2 Pogledi
• 07/10/23
0
0
Ugraditi
administrator
Pretplatnici
The immune checkpoint inhibitor Opdivo (nivolumab) has been shown to increase survival for patients with metastatic clear cell kidney cancer (also called renal cell carcinoma, or RCC).
Prikaži više
Komentari na Facebooku
SORT BY-
Najbolji komentari
-
Najnoviji komentari